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Background: Severe acute respiratory syndrome (SARS) is an emerging viral infectious disease. We report our
experience in treating SARS patients.
Methods: From April 27 to May 24, 2003, a total of 36 patients with probable SARS were admitted and treated
in a hospital rearranged as a special center for the management of SARS patients. Medical records for the patients
were retrospectively reviewed. Univariate and multivariate analyses were performed to determine factors associated
with respiratory failure and intubation.
Results: Of the 36 patients with probable SARS (median age, 37 years; range, 22–66 years), 9 were male and
27 were female. Thirty-two patients (88.9%) were infected in the hospital setting. All patients presented with fever,
and 33 eventually developed lymphopenia during hospitalization. Chest radiography showed no unique pattern, but
pleural effusion was not seen. All patients initially received empiric antibacterial therapy against common causative
pathogens of atypical pneumonia. Ribavirin was given to all except 1 patient. Twenty-two patients received
immunoglobulin therapy, and 32 were given corticosteroids. A total of 20 patients (55.6%) required supplemental
oxygen, and 8 (22.2%) were intubated with mechanical ventilatory support. Two of these patients died. A higher
body temperature at presentation (median 39.5 vs 38.6ºC), and higher peak values of lactate dehydrogenase (410
vs 282 U/L) and C-reactive protein (10.2 vs 2.5 mg/dL), were associated with subsequent respiratory failure.
Multivariate analysis showed that peak level of C-reactive protein was the only independent predictor of respiratory
failure and intubation (odds ratio for every increment of 1 mg/dL = 1.45; 95% confidence interval = 1.003, 2.097;
p = 0.048).
Conclusion: All patients with probable SARS who were admitted to hospital presented with fever and lymphopenia.
While the efficacy of different treatments could not be evaluated from this retrospective study, a higher value of
C-reactive protein was associated with the development of respiratory failure and subsequent intubation. [J Chin
Med Assoc 2005;68(3):110–117]
Key Words: clinical characteristics, C-reactive protein, prognostic factors, severe acute respiratory syndrome (SARS)
Clinical Characteristics, Management and
Prognostic Factors in Patients with Probable Severe
Acute Respiratory Syndrome (SARS) in a
SARS Center in Taiwan
Chun-Yu Liu1, Lin-Ju Huang2, Chung-Hsu Lai2, Hsin-Pai Chen2, Te-Li Chen2,3*,
Chang-Phone Fung2,3, Cheng-Yi Liu2,3
1Department of Medicine, 2Section of Infectious Diseases, Taipei Veterans General Hospital, and
3National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
©2005 Elsevier. All rights reserved.
Introduction
In November 2002, 305 cases of highly contagious,
rapidly progressive and sometimes fatal atypical
pneumonia of unknown cause were reported from
Guangdong Province in southern China.1 In March
2003, as the condition began to spread from China,
the World Health Organization (WHO) issued a
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initially met the criteria for suspected SARS, but who
were later reclassified as probable cases, were also
included. Patients who had another diagnosis for their
pneumonia were excluded.
Study protocol
The medical records of patients were reviewed
retrospectively: data about demographics, clinical
characteristics, laboratory data, chest radiography,
treatment and outcomes were analyzed. Whole blood-
cell counts and serum biochemistry for all patients
were examined using automatic machines and standard
methods. An independent radiologist read and reported
on all chest radiographs. Sputum and blood samples
from all patients were sent for bacterial culture. Samples
for SARS-virus assays (including nasopharyngeal
swabs, serum and urine samples), and for serologic test-
ing for the common pathogens of atypical pneumonia
(Mycoplasma spp., Chlamydia spp., and Legionella
spp.), were taken and sent to laboratories of the
Taiwan Center for Disease Control, after which cases
were reported to the sanitary authorities in Taiwan.
Leukopenia was defined as a white blood-cell count
< 3,500/+L, lymphopenia as a lymphocyte count
< 1,000/+L, and thrombocytopenia as a platelet count
< 150,000/+L.
Statistical analyses
Continuous data were presented as median values and
ranges, unless stated otherwise. Factors associated
with respiratory failure requiring intubation were
determined. Fisher’s exact test was used for analysis of
categorical variables, and the Mann-Whitney test for
that of continuous variables. All analyses were carried
out using Statistical Package for the Social Sciences
version 10.0 for Windows (SPSS Inc, Chicago, IL,
USA). Factors with a p value of less than 0.1 were
included in a multivariate analysis, by using stepwise
logistic regression, to identify independent risk factors
for the development of respiratory failure and subse-
quent intubation. A p value of less than 0.05 was con-
sidered significant; all probabilities were 2-tailed.
Results
Study population
During the study period, a total of 206 patients were
referred to the Armed Forces Sung-Shan Hospital.
Thirty-six patients met WHO criteria and were included
in the analysis. Nine patients were male and 27 female,
with ages ranging from 20–66 years (median, 37
years). Thirty-two patients (88.9%) were health care
global alert about outbreak of the illness, which was
named severe acute respiratory syndrome (SARS). At
this time, there were known SARS cases in China
(both the mainland and the special administrative
region of Hong Kong), Vietnam, Singapore, and
Canada. By May 31, 2003, a cumulative total of 8,360
cases of SARS, with 764 deaths, had been reported by
30 countries.2
The first probable case of SARS reported in Taiwan
was that of a 54-year-old businessman who traveled to
Guangdong Province and returned to Taipei, via
Hong Kong, on February 21, 2003.3 From the begin-
ning of March, Taiwan experienced a gradual increase
in the number of probable cases of SARS. Initially,
most reported cases were either imported or seconda-
ry.3 However, the number increased markedly at the
end of April, when local transmission in hospitals
became the source of most new infections. Up to June
27, 2003, there was a cumulative total of 681 probable
SARS cases in Taiwan, with 84 deaths. However, few
articles were written describing the clinical characteris-
tics and management of SARS patients in Taiwan.4–8
This study delineates clinical features, laboratory data,
chest radiography, management and outcomes for
patients with probable SARS at a SARS center in
Taipei, and determines factors associated with respira-
tory failure and subsequent intubation in such patients.
Methods
Study population
The Armed Forces Sung-Shan Hospital is a local
community hospital, with about 500 beds, and is
located in Taipei City. During the outbreak of SARS
in Taiwan, the hospital was rearranged as a special
center for the management of SARS patients from
April 27, 2003. The hospital was equipped with rough-
ly 70 isolation rooms with negative pressure. Strict
infection-control measures were established when
caring for patients with probable SARS.
Patients were referred from other hospitals when a
diagnosis, according to the WHO definition, was
made of suspected SARS (fever, cough, or breathing
difficulty; and a known history of exposure to SARS
patients, or travel to an area with local transmission of
SARS) or probable SARS (radiographic evidence of
pneumonia or respiratory distress syndrome [RDS];
an autopsy result of RDS without identifiable cause; or
a positive result of * 1 assays for SARS-associated
coronavirus).9 Patients admitted from April 27 to May
24, 2003, and who met WHO criteria for probable
SARS, were included in the analysis. Patients who
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workers, patients or hospital visitors who were exposed
to SARS patients in the hospital setting; 18 (50%) were
medical staff. Seven patients had underlying disease:
diabetes mellitus (n = 2); cardiovascular disease (1);
ovarian teratoma (1); hydronephrosis (1); thyroid
disease (1); and diabetes plus gallstones (1). Four
patients had a history of smoking, and 3 of these
consumed alcohol frequently.
Clinical characteristics
The patients had had symptoms for a median of
2 days (range, 0–8 days) before admission. The most
common symptoms at presentation were fever (100%),
chills (75%), non-productive cough (44.4%), diarrhea
(41.7%), myalgia (38.9%), and productive cough
(19.4%). Less common presenting symptoms includ-
ed headache (8.3%), sore throat (5.6%), and shortness
of breath (2.8%). The mean body temperature of
patients recorded at admission was 38.8ºC (38.0–
40.1ºC).
Initial laboratory indices showed leukopenia in
19.4% of patients. Twenty-seven patients (75%) had a
normal neutrophil count (2,000–7,500/+L) and
24 (66.7%) had a normal monocyte count (200–
700/+L). However, 23 patients (63.9%) had lym-
phopenia, and 17 (47.2%) had thrombocytopenia at
presentation. Thirty-three patients (91.7%) developed
lymphopenia after a median of 8 days (range, 1–
29 days) from the onset of symptoms. During ad-
mission, lactate dehydrogenase (LDH) was measured
in 30 patients, and 20 (66.7%) had elevated values
(> 200 U/L). Other laboratory indices at presentation
are shown in Tables 1 and 2. During the course of
illness, several laboratory parameters, including LDH,
creatine kinase (CK), alanine aminotransferase (ALT),
and C-reactive protein (CRP), were elevated (Table
1). The highest peak values for LDH (14,770 U/L)
and CK (24,949 U/L) were noted in a 49-year-old
female after intubation. These markedly abnormal
values were attributed to multi-organ failure, which
resulted in death. The results of sputum culture revealed
either no growth or growth of normal mixed flora in
all cases, and no blood cultures or serologic tests were
positive. Among the 28 patients whose nasopharyngeal
swabs were tested for SARS-associated coronavirus by
real-time polymerase chain reaction (RT-PCR), 15
(53.6%) had positive results, and 5 of these had viruses
isolated from viral culture.
Radiographic findings
The initial chest radiographs showed normal findings
in 11 patients (30.6%), unifocal infiltration in 17
(47.2%), and multifocal or bilateral involvement in 8
(22.2%) (Figures 1–4). Peripheral-zone involvement
Table 1. Initial and highest values [median (range)] of laboratory data in 36 patients with probable SARS
Laboratory data On admission Peak value during hospitalization
Leukocyte count, /+L 4,940 (2,140–18,380) 12,990 (5,220–44,500)
Lymphocyte count, /+L 4,844 (202–1,921) sa4,sa4,ND
Platelet count, =103/+L 4,152 (91–271) sa4,sa4,ND
LDH, U/L* 4,249 (127–909) a4,324 (167–14,770)
CK, U/L a4,81 (20–461) a4,114 (20–24,949)
ALT, U/L a4,28 (5–141) sa4,46 (6–184)
CRP, mg/dL ,4,2.0 (0.3–10.4) sa44.9 (0.5–26.2)
*Only 30 patients had LDH measured at admission.
ALT = alanine aminotransferase; CK = creatine kinase; CRP = C-reactive protein; LDH = lactate dehydrogenase; ND = no data.
Table 2. Laboratory abnormalities on admission and during hospitalization in 36 patients with probable SARS
Laboratory data (abnormal value) On admission, n (%) During hospitalization, n (%)
Leukopenia (< 3,500/+L) 7 (19.4) 17 (47.2)
Lymphopenia (< 1,000/+L) 23 (63.9) 33 (91.7)
Thrombocytopenia (< 150 = 103/+L) 17 (47.2) 21 (58.3)
LDH (> 200 U/L)* 20 (66.7) 31 (86.1)
CK (men > 170 U/L; women > 120 U/L) 11 (30.6) 19 (52.8)
ALT (> 40 U/L) 8 (22.2) 22 (61.1)
CRP (> 0.5 mg/dL) 22 (61.1) 35 (97.2)
*Only 30 patients had LDH measured at admission.
ALT = alanine aminotransferase; CK = creatine kinase; CRP = C-reactive protein; LDH = lactate dehydrogenase.
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Figure 1. Frontal chest radiograph of a 20-year-old male, taken 4
days after symptom onset, showing a pleural-based consolidation
over the right upper lung field.
Figure 2. Frontal chest radiograph of a 27-year-old female, taken
8 days after symptom onset, showing ground-glass infiltration in
the left-middle lung zone.
Figure 4. Chest radiograph of a 29-year-old female (see also Figure
3) that progressed after 6 days to extensive, bilateral air-space
opacities resembling the radiographic pattern of adult respiratory
distress syndrome. The patient died 15 days after symptom onset.
Figure 3. Frontal chest radiograph of a 29-year-old female, taken
7 days after symptom onset, showing patchy infiltration in both
lung fields.
with focal consolidation or ground-glass appearance
were the most common infiltration patterns. Chest
radiographs remained normal throughout the hospital
course in a 49-year-old male who presented with dry
cough and a positive RT-PCR result. However,
radiographs progressed from normal or unifocal
infiltration to unilateral, multifocal or bilateral
involvement in 14 of the 28 patients (50%) during
hospitalization (Table 3). Radiographic progression
occurred in 25 patients (69.4%) and reached a peak 8
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days (median; range, 5–20 days) after the onset of
symptoms. In the 8 patients with respiratory failure
and who were intubated, chest radiographs showed
multifocal lesions in all cases, but in the 28 patients
who were not intubated, only 13 (46.4%) had such
lesions (p = 0.012).
Treatment
All patients received empiric antibacterial therapy,
such as a macrolide or fluoroquinolone, to provide
coverage against the common pathogens of atypical
pneumonia. All except 1 patient received ribavirin
(loading dose 2 g, followed by 1–1.2 g/day for 10 days
[median; range, 3–18 days]) within 0–7 days (median,
1 day) of hospitalization. Patients with persistent
fever, clinical deterioration, or progressive chest-
radiograph changes were treated with intravenous
immunoglobulin (IVIG) 500 mg/kg/day for 2 days
and/or methylprednisolone 2–4 mg/kg/day, with
stepwise dosage tapering for a median total duration of
6 days (range, 3–45 days). Seven intubated patients
and 15 non-intubated patients received IVIG (p =
0.115), while methylprednisolone was used in all
intubated patients and 24 non-intubated patients.
Corticosteroid therapy was started a median of 4 days
(range, 1–10 days) after, and IVIG a median of 6 days
(range, 2–19 days) after, symptom onset. There were
no significant differences between the intubated and
non-intubated groups regarding the times of starting
IVIG (7 vs 6 days) and corticosteroids (3 vs 6 days).
However, methylprednisolone was given to the
intubated versus non-intubated group for a longer
period (20 vs 5 days; p = 0.004). Patients who developed
hypoxemia (oxygen saturation < 90% under room air)
were oxygenated through a nasal cannula, or intubated,
as necessary. A total of 20 patients (55.6%) required
oxygen therapy and, of the entire cohort, 8 patients
(22.2%) were intubated and received mechanical
ventilation a median of 8 days (range, 5–15 days) after
symptom onset.
Clinical outcomes
By June 11, 2003, only 1 patient was hospitalized and
receiving mechanical ventilation. Two patients died of
severe acute RDS, 14 (38.9%) recovered with com-
plete resolution of chest radiographs, and 19 (52.8%)
recovered but still had abnormal chest radiographs at
discharge. Excluding the patient who was hospitalized,
the median duration of hospital stay was 19 days
(range, 7–41 days). Intubated versus non-intubated
patients were hospitalized for longer (median 22 vs 15
days; p = 0.048).
Factors associated with respiratory failure
Univariate analysis of categorical (Table 4) and
continuous variables (Table 5) showed that higher
body temperature at presentation (median 39.5 vs
38.6ºC), and higher peak levels of LDH (410 vs
282 U/L) and CRP (10.2 vs 2.5 mg/dL), were associ-
ated with respiratory failure in SARS patients. In the
multivariate analysis, however, only peak level of CRP
remained an independent predictor of respiratory failure
(odds ratio for every increment of 1 mg/dL, 1.45; 95%
confidence interval, 1.003–2.097; p = 0.048).
Discussion
Patients with suspected SARS were not included in the
present study because of the low specificity of clinical
criteria for suspected SARS. In addition, a recent study
showed that the positive predictive value of WHO
criteria for suspected SARS was only 54% (39–69%).10
We found that the clinical features of our patients
were similar to those reported in other studies: fever,
chills and dry cough were the most common initial
Table 3. Changes in chest radiographs in 36 patients with probable SARS
Initial chest radiograph n (%) Progression of radiograph n (%)
Normal 11 (30.6) No change 1 (9.1)
Unifocal infiltration 13 (27.3)
Multifocal infiltration 117 (63.6)*
Unifocal infiltration 17 (47.2) No change 10 (58.8)
Multifocal infiltration 1 7 (41.2)†
Multifocal infiltration  18 (22.2)‡ No change 0 (0) 1
Multifocal infiltration (increased area of involvement > 25%) 1 8 (100)*
*All patients had bilateral lung involvement; †2 patients had unilateral, multifocal lung involvement; ‡1 patient had unilateral, multifocal infiltration
and 7 others had bilateral, multifocal lung involvement.
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presentations.10–13 Approximately 1-half to 2-thirds of
the patients presented with moderate lymphopenia
(63.9%), mild thrombocytopenia (47.2%), and an
elevated LDH level (66.7%), on admission. Interest-
ingly, all but 3 patients developed lymphopenia during
hospitalization, and in most cases, this occurred during
the second week of the disease. This finding is consistent
with that found by Wong et al, who proposed that
lymphocyte depletion might result from a direct effect
of the virus, or various cytokines, on lymphocytes.14
Panesar suggested that lymphocyte margination due
to glucocorticosteroid therapy or stimulation of the
hypothalamic-pituitary-adrenal axis might be another
explanation for lymphopenia,15 while O’Donnell et al
pointed out that apoptosis might also play a role.16
The chest radiograph presentations in our study are
also compatible with findings in previous studies.11,12,17
In the early disease stages, a peripheral/pleural-based
opacity may be the only abnormality. This may range
from a ground-glass appearance to consolidation.
Unilateral (50%) infiltration is more common than
bilateral or multifocal infiltration in the initial pre-
sentation, whereas cavitation and pleural effusion are
not features of this disease. The radiographic involve-
Table 4. Categorical variables for SARS patients with or without respiratory failure
Variable
ETT + MV (N = 8) No ETT + MV (N = 28) p
n (%) n (%)
Gender (male/female) 2/6 7/21 1.000
In-hospital exposure* 7 (87.5) 26 (92.9) 0.553
Medical staff 5 (62.5) 13 (46.4) 0.691
Comorbid disease 3 (37.5) 15 (17.9) 0.346
Smoking 1 (12.5) 13 (10.7) 1.000
Alcohol 1 (12.5) 2 (7.1) 0.553
Multifocal radiographic involvement on presentation 3 (37.5) 15 (17.9) 0.346
*Exposed to SARS in the hospital setting (health care workers, patients, or visitors).
ETT = endotracheal tube intubation; MV = mechanical ventilation.
Table 5. Continuous variables associated with respiratory failure and subsequent intubation in 36 patients with probable SARS
Variable
ETT + MV (N = 8) No ETT + MV (N = 28)
p
Median (range) Median (range)
Age, yr 34 (22–66) 37 (20–66) 0.531
Initial body temperature, ºC 39.5 (38.0–40.1) 38.6 (38.0–40.0) 0.013
Interval between symptom onset and admission, d 2 (1–5) 2 (0–8) 0.752
On admission
   Leukocyte count, /+L 4,155 (2,200–13,830) 5,040 (2,140–18,380) 0.384
   Lymphocyte count, /+L 843 (202–1,921) 844 (300–2,642) 0.832
   Platelet count, =103/+L 145 (97–196) 152 (91–271) 0.446
   LDH, U/L 375 (130–641) 240 (127–909) 0.845
   CK, U/L 108 (62–461) 71 (20–436) 0.178
   ALT, U/L 30 (14–52) 27 (5–141) 0.817
   CRP, mg/dL 3.4 (0.3–10.4) 2.0 (0.5–10.4) 0.916
Peak values*
   Leukocyte count, /+L 12,015 (3,900–20,290) 12,740 (5,220–25,270) 0.451
   LDH, U/L 410 (303–2,103) 282 (167–1,315) 0.021
   CK, U/L 119 (20–461) 83 (20–1,966) 0.530
   ALT, U/L 38 (20–78) 42 (6–183) 0.765
   CRP, mg/dL 10.2 (5.4–20.4) 2.5 (0.5–18.0) 0.001
   Duration of ribavirin therapy, d 11 (3–18) 10 (3–17) 0.450
*In the intubated group, peak values were the highest values collected before intubation.
ALT = alanine aminotransferase; CK = creatine kinase; CRP = C-reactive protein; ETT = endotracheal tube intubation; LDH = lactate dehydrogenase;
MV = mechanical ventilation.
C.Y. Liu, et al
116 J Chin Med Assoc • March 2005 • Vol 68 • No 3
ment usually progresses to bilateral infiltration,
including a pattern compatible with adult RDS.4,5,18–20
Our univariate analysis showed that initial, multifocal,
radiographic involvement was not associated with the
development of respiratory failure (p = 0.346). Peiris
et al also showed that neither apparently normal nor
multilobar involvement on chest radiograph at
admission was associated with the development of
adult RDS.13
In the current, retrospective study of a small number
of patients, the efficacy of different treatments could
not be elucidated. IVIG has been used in combination
therapy for respiratory syncytial virus (RSV) pneumonia
and cytomegalovirus pneumonia in bone marrow
transplant recipients, and for treating RSV pneumonia
in selected infants and children.21–24 IVIG has also
demonstrated efficacy in the treatment of other viral
pneumonias.25–27 Nevertheless, our preliminary results
showed that, in SARS patients, the development of
respiratory failure was not associated with less frequent
or delayed use of IVIG.
The mortality rate in our study was 5.6% (2 patients),
which is lower than the average reported by the WHO
(14–15%).28 This lower rate may be due to the age
distribution in our study, which comprised patients of
a younger age than in other trials. In addition, few of
our patients had comorbid diseases associated with a
poor prognosis.
Our study showed that higher body temperature
on presentation, and higher peak LDH and CRP levels
during hospitalization, were associated with respiratory
failure and mechanical ventilation. However, only
peak CRP level was independently associated with
poor outcome. CRP, which has various biologic
properties and functions,29 has a disputed role as a
marker of infection and/or inflammation in daily
clinical practice. A study of community-acquired
pneumonia showed that high interleukin-6 or CRP
levels were associated with a long duration of fever and
hospital stay, and less frequent clinical or radiographic
recovery during follow-up after discharge.30 Moreover,
elevated serum levels of CRP on admission to the
intensive care unit correlate with an increased risk of
organ failure and death, and persistently high CRP
levels correlate with a poor outcome in critically ill
patients.31 We suggest that CRP might reflect the
severity of inflammation caused by the SARS virus and
be related to immunopathologic damage to the lung,
thus predicting a poor outcome.
SARS is an emerging viral disease, many aspects of
which are being studied. In this retrospective study, a
high value of CRP was associated with the development
of respiratory failure and subsequent intubation.
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